- Health
- Parenting
- Style and beauty
- Horoscopes
- Shopping
- Food
- Travel
- Autos
- Gift ideas
- Buying guides
- My Portfolio
- News
- Markets
- Stocks: Most Actives
- Stocks: Gainers
- Stocks: Losers
- Trending Tickers
- Futures
- World Indices
- US Treasury Bonds Rates
- Currencies
- Crypto
- Top ETFs
- Top Mutual Funds
- Options: Highest Open Interest
- Options: Highest Implied Volatility
- Sectors
- Basic Materials
- Communication Services
- Consumer Cyclical
- Consumer Defensive
- Energy
- Financial Services
- Healthcare
- Industrials
- Real Estate
- Technology
- Utilities
- Private Companies
- Research
- Personal Finance
- Videos
- Watch Now
- Fantasy
- Daily fantasy
- NFL
- NBA
- MLB
- NHL
- College football
- College basketball
- Soccer
- NFL Draft
- Yahoo Sports AM
- Show all
© 2025 All rights reserved.
Acadia Nuplazid patent ruling removes ‘key overhang,’ says BMO Capital
TipRanks
Sat, May 17, 2025, 1:36 PM 1 min read
In This Article:
BMO Capital analyst Evan Seigerman notes that a U.S. district court issued a ruling in favor of Acadia Pharmaceuticals (ACAD) in their Nuplazid patent infringement lawsuit with Aurobindo, confirming today that Aurobindo infringed on claims 4 and 5 of Acadia’s 11,452,721 U.S. formulation patent. Today’s announcement likely extends the lifespan of pimavanserin and could extend the company’s patent protection from 2030 to 2038, removing a “key overhang,” says the analyst, who reiterates an Outperform rating and $24 price target on Acadia shares.
Confident Investing Starts Here:
-
Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
-
Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ACAD:
Disclaimer & DisclosureReport an Issue
-
Acadia Pharmaceuticals price target raised to $30 from $27 at Needham
-
ACADIA Pharmaceuticals: Buy Rating Affirmed Amid Legal Victory and Promising R&D Prospects
-
District court finds Aurobindo infringes Acadia Pharmaceuticals patent claims
-
Acadia Pharmaceuticals files to sell 43.58M shares of common stock for holders
Terms and Privacy Policy
Comments